Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 1, 2025

Anti-Chk2, phospho (Thr68) Antibody, Unconjugated

RRID:AB_331479 Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 2661, RRID:AB_331479)

Antibody Information

URL: http://antibodyregistry.org/AB_331479

Proper Citation: (Cell Signaling Technology Cat# 2661, RRID:AB_331479)

Target Antigen: Chk2, phospho (Thr68)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, IF-IC, F. Consolidation: AB_10828205, AB_331480.

Antibody Name: Anti-Chk2, phospho (Thr68) Antibody, Unconjugated

Description: This polyclonal targets Chk2, phospho (Thr68)

Target Organism: monkey, human

Antibody ID: AB_331479

Vendor: Cell Signaling Technology

Catalog Number: 2661

Alternative Catalog Numbers: 2661P, 2661T, 2661S, 2661L

Record Creation Time: 20231110T044857+0000

Record Last Update: 20241114T230541+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Chk2, phospho (Thr68) Antibody, Unconjugated.

No alerts have been found for Anti-Chk2, phospho (Thr68) Antibody, Unconjugated.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 43 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Liu J, et al. (2024) The phosphorylation-deubiquitination positive feedback loop of the CHK2-USP7 axis stabilizes p53 under oxidative stress. Cell reports, 43(6), 114366.

Rona G, et al. (2024) CDK-independent role of D-type cyclins in regulating DNA mismatch repair. Molecular cell.

Celli L, et al. (2024) CRISPR/Cas9 mediated Y-chromosome elimination affects human cells transcriptome. Cell & bioscience, 14(1), 15.

Liu Z, et al. (2024) FANCM promotes PARP inhibitor resistance by minimizing ssDNA gap formation and counteracting resection inhibition. Cell reports, 43(7), 114464.

Boddu PC, et al. (2024) Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape. Molecular cell, 84(8), 1475.

Galsky MD, et al. (2024) Immunomodulatory effects and improved outcomes with cisplatinversus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer. Cell reports. Medicine, 5(2), 101393.

Ramadan WS, et al. (2024) Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives. iScience, 27(1), 108659.

Ratnayeke N, et al. (2023) CDT1 inhibits CMG helicase in early S phase to separate origin licensing from DNA synthesis. Molecular cell, 83(1), 26.

Moreno SP, et al. (2023) TZAP overexpression induces telomere dysfunction and ALT-like activity in ATRX/DAXX-deficient cells. iScience, 26(4), 106405.

Apaydin T, et al. (2023) WIP1 is a novel specific target for growth hormone action. iScience, 26(11), 108117.

Guardamagna I, et al. (2023) Asparagine and Glutamine Deprivation Alters Ionizing

Radiation Response, Migration and Adhesion of a p53null Colorectal Cancer Cell Line. International journal of molecular sciences, 24(3).

Huang M, et al. (2023) FACS-based genome-wide CRISPR screens define key regulators of DNA damage signaling pathways. Molecular cell, 83(15), 2810.

Meibers HE, et al. (2023) Effector memory T cells induce innate inflammation by triggering DNA damage and a non-canonical STING pathway in dendritic cells. Cell reports, 42(10), 113180.

Zhao R, et al. (2023) Nuclear ATR lysine-tyrosylation protects against heart failure by activating DNA damage response. Cell reports, 42(4), 112400.

Liu J, et al. (2023) ATM-CHK2-TRIM32 axis regulates ATG7 ubiquitination to initiate autophagy under oxidative stress. Cell reports, 42(11), 113402.

Dullovi A, et al. (2023) Microtubule-associated proteins MAP7 and MAP7D1 promote DNA double-strand break repair in the G1 cell cycle phase. iScience, 26(3), 106107.

Wilson GA, et al. (2023) Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition. Molecular cell, 83(22), 4078.

Qin T, et al. (2022) ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. Cell reports, 38(2), 110216.

Amatullah H, et al. (2022) Epigenetic reader SP140 loss of function drives Crohn's disease due to uncontrolled macrophage topoisomerases. Cell, 185(17), 3232.

Papadopoulos D, et al. (2022) MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts. Molecular cell, 82(1), 159.